Vivanza Biosciences Ltd
Vivanza Biosciences Ltd Live Price Chart
Vivanza Biosciences Ltd Technicals
| 20 Day | ₹ 2.107 |
| 50 Day | ₹ 2.130 |
| 100 Day | ₹ 2.146 |
| 200 Day | ₹ 2.366 |
| 20 Day | ₹ 2.125 |
| 50 Day | ₹ 2.138 |
| 100 Day | ₹ 2.121 |
| 200 Day | ₹ 2.157 |
Vivanza Biosciences Ltd Performance
| Previous Close | ₹ 2.04 |
| High | ₹ 2.05 |
| Volume | 4085 |
| 52W Range | ₹ 1.9 - ₹ 2.94 |
| Open | ₹ 2.05 |
| Low | ₹ 2.05 |
| Market Cap | ₹ 9 Cr |
Vivanza Biosciences Ltd Fundamentals
| ROCE | -1.312 |
| P/E Ratio | -18.640 |
| P/B Ratio | 1.820 |
| Industry P/E | 1.820 |
| Debt to Equity | 39.451 |
| ROE | -9.911 |
| EPS | -0.110 |
| Dividend Yield | 0.000 |
| Book Value | 1.125 |
| Face Value | 1.000 |
Vivanza Biosciences Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 2.9774 | 14.4673 | 14.5939 | 9.9756 | 9.7228383 |
| Total Expenses | 3.671 | 14.0384 | 13.9067 | 9.5115 | 9.574833 |
| Profit After Tax | -0.6951 | 0.3174 | 0.5691 | 0.4637 | 0.0998546 |
Vivanza Biosciences Ltd Shareholding Pattern
| Promoter Holdings | 20.020 % |
| FIIs | 0.000 % |
| DIIs | 0.002 % |
| MutualFund | 0.000 % |
| Retail | 73.421 % |
| Others - | 6.558 % |
About Vivanza Biosciences Ltd
History of Vivanza Biosciences Ltd
Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. It is presently engaged in the business of Pharmaceutical Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. Company undertook an expansion-cum-diversification programme to increase its capacity from 18 lac pa to 54 lac pa. It came out with a public issue of 21,70,000 equity shares of Rs 10 each for cash at par aggregating Rs 217 lac. It is one of the few companies which has facilities for both glass as well as plastic containers. The Company acquired 100% Equity Shares of Vivanza Lifesciences Private Limited, making it a Wholly Owned Subsidiary w.e.f. 17 June, 2016. ...
